(secondQuint)Open-Label Rollover Study of PBI 4050 in Subjects With Alstrm Syndrome.

 This is a Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alstrom Syndrome who have completed the end-of-treatment (EoT) visit in a preceding ProMetic-sponsored Alstrom Syndrome study with PBI-4050.

 This study will also evaluate the efficacy and pharmacological effects of PBI 4050 in this multi faceted disorder.

 Approximately 20 to 30 subjects will be enrolled to receive 800 mg PBI-4050 once daily for 96 weeks or until product licensing or study termination by the Sponsor, whichever occurs first.

.

 Open-Label Rollover Study of PBI 4050 in Subjects With Alstrm Syndrome@highlight

Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alstrom Syndrome who have completed a preceding ProMetic-sponsored Alstrom Syndrome study with PBI-4050.

